Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes

Area of Science:

• Cardiovascular Medicine
• Biomarker Discovery
• Clinical Research

Background:

• CD31+/Annexin V+ microparticles (MPs) are elevated in individuals with cardiovascular risk factors and impaired endothelial function.
• Previous studies suggest a link between MPs and endothelial dysfunction.

Purpose of the Study:

• To determine if CD31+/Annexin V+ MPs serve as an independent predictor of cardiovascular events in patients with stable coronary artery disease (CAD).
• To assess the utility of MPs in cardiovascular risk stratification for CAD patients.

Main Methods:

• Flow cytometry was used to quantify CD31+/Annexin V+ MP levels in 200 stable CAD patients.
• Patients were followed for a median of 6.1 years for major adverse cardiovascular and cerebral events (MACCE).
• Multivariate analysis was performed, adjusting for traditional cardiovascular risk factors.

Main Results:

• Higher MP levels were observed in patients who experienced MACCE compared to those who did not (P=0.004).
• Elevated MP levels were independently associated with increased risk of cardiovascular death (HR 4.0), revascularization (HR 2.4), and first MACCE (HR 2.3).
• Inclusion of MP levels improved the predictive accuracy of a traditional cardiovascular risk model (c-statistic increased from 0.637 to 0.702).

Conclusions:

• Circulating CD31+/Annexin V+ MPs are an independent predictor of cardiovascular events in stable CAD.
• MP levels may enhance the risk stratification of patients with stable coronary artery disease.